You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,420,749

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,420,749

Title:	Crystalline form of lorlatinib free base
Abstract:	This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H- -8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
Inventor(s):	Pencheva; Klimentina Dimitrova (Sandwich, GB), Birch; Melissa J. (Sandwich, GB)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	15/743,894
Patent Claims:	1. A crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2- H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbo- nitrile (lorlatinib) free base, having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2.theta. values of: 9.6, 10.1 and 16.2 .degree.2.theta..+-.0.2 .degree.2.theta.. 2. The crystalline form of claim 1, having a PXRD pattern further comprising a peak at the 2.theta. value of: 17.3 .degree.2.theta..+-.0.2 .degree.2.theta.. 3. The crystalline form of claim 2, having a PXRD pattern further comprising a peak at the 2.theta. value of: 14.3 .degree.2.theta..+-.0.2 .degree.2.theta.. 4. The crystalline form of claim 1, having a Raman spectrum comprising wavenumber (cm.sup.-1) values of: 2229 and 2240 cm.sup.-1.+-.2 cm.sup.-1. 5. The crystalline form of claim 1, having a .sup.13C solid state NMR spectrum comprising resonance (ppm) values of: 39.1 and 142.1 ppm.+-.0.2 ppm. 6. The crystalline form of claim 1, having a .sup.19F solid state NMR spectrum comprising resonance (ppm) values of: -108.2 and -115.2 ppm.+-.0.2 ppm. 7. A crystalline form of lorlatinib free base, having a Raman spectrum comprising wavenumber (cm.sup.-1) values of: 2229 and 2240 cm.sup.-1.+-.2 cm.sup.-1. 8. The crystalline form of claim 7, having a Raman spectrum further comprising the wavenumber (cm.sup.-1) value of: 1619 cm.sup.-1.+-.2 cm.sup.-1. 9. The crystalline form of claim 8, having a Raman spectrum further comprising the wavenumber (cm.sup.-1) value of: 1553 cm.sup.-1.+-.2 cm.sup.-1. 10. The crystalline form of claim 9, having a Raman spectrum further comprising the wavenumber (cm.sup.-1) value of: 774 cm.sup.-1.+-.2 cm.sup.-1. 11. The crystalline form of claim 7, having a .sup.13C solid state NMR spectrum comprising resonance (ppm) values of: 39.1 and 142.1 ppm.+-.0.2 ppm. 12. The crystalline form of claim 7, having a .sup.19F solid state NMR spectrum comprising resonance (ppm) values of: -108.2 and -115.2 ppm.+-.0.2 ppm. 13. A crystalline form of lorlatinib free base, having a .sup.13C solid state NMR spectrum comprising two or more resonance (ppm) values of: 39.1 and 142.1 ppm.+-.0.2 ppm. 14. The crystalline form of claim 13, having a .sup.13C solid state NMR spectrum further comprising the resonance (ppm) value of: 112.3 ppm.+-.0.2 ppm. 15. The crystalline form of claim 14, having a .sup.13C solid state NMR spectrum further comprising the resonance (ppm) value of: 25.8 ppm.+-.0.2 ppm. 16. The crystalline form of claim 15, having a .sup.13C solid state NMR spectrum further comprising the resonance (ppm) value of: 117.7 ppm.+-.0.2 ppm. 17. A crystalline form of lorlatinib free base, having a .sup.19F solid state NMR spectrum comprising a resonance (ppm) value selected from the group consisting of: -108.2 and -115.2 ppm.+-.0.2 ppm. 18. A pharmaceutical composition comprising the crystalline form of lorlatinib free base according to claim 1, and a pharmaceutically acceptable carrier or excipient. 19. A method of treating abnormal cell growth in a mammal comprising administering to the mammal a therapeutically effective amount of the crystalline form of lorlatinib free base according to claim 1, wherein the abnormal cell growth is cancer mediated by anaplastic lymphoma kinase (ALK) or c-ros oncogene 1 receptor tyrosine kinase (ROS1). 20. The method of claim 19, wherein the cancer is non-small cell lung cancer (NSCLC).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.